register

News & Trends - MedTech & Diagnostics

Diagnostic company secures regulatory green light for detection of life-threatening condition

Health Industry Hub | January 24, 2024 |

MedTech & Diagnostics News: A Brisbane-based molecular diagnostic company has announced the regulatory clearance of its test for sepsis by the Therapeutic Goods Administration (TGA).

The Cost of Sepsis in Australia report shed light on the staggering statistics surrounding sepsis cases, estimating over 90,000 instances annually with direct and indirect costs reaching $700 million and $4 billion respectively.

Early identification of sepsis is difficult for many reasons. In the early stages of the disease, patients present with inflammatory clinical signs which may be early indicators of a septic response, but which are also common to many other non-infectious conditions. Proof of infection by the conventional ‘gold standard’ criterion of culture positivity lacks timeliness and cultures are negative in a significant fraction of retrospectively diagnosed sepsis cases.

With this regulatory green light, SeptiCyte RAPID addresses a clinical need for more rapid and accurate differentiation of sepsis from infection-negative systemic inflammation response syndrome (SIRS) within a clinically actionable (~1 hour) timeframe.

Associate Professor Adam Irwin, Principal Research Fellow and NHMRC Emerging Leadership Fellow in paediatric infectious disease at The University of Queensland and Queensland Children’s Hospital, expressed anticipation for the practical implications of SeptiCyte RAPID. Having trialled the technology over the past few years, with funding through the Medical Research Future Fund (MRFF) Genomic Health Futures Mission, he highlighted its potential to significantly influence clinical practice.

“It is especially gratifying to introduce our product to the Australian healthcare community because it was conceived in Australia by Immunexpress’ Chief Scientific Officer Dr Richard Brandon. The ability to bring our sepsis diagnostic capabilities into the Australian healthcare system marks the latest victory in our growing momentum towards impacting patient lives worldwide,” said Dr Rollie Carlson, CEO of Immunexpress.

Recognising the urgency of serving patients suspected of sepsis, he stressed the need for swift and precise diagnostics.

“There’s an urgent need to serve this vulnerable patient group, which has pushed us to continue to revolutionise diagnostic capabilities for their critical care,” Dr Carlson said.

Immunexpress has strategically partnered with Abacus Diagnostics to facilitate the sale and distribution of SeptiCyte RAPID across Australia. Abacus Diagnostics, a distributor for the Biocartis Idylla™ Platform in Australia, aligns with Immunexpress in their mission to make innovative diagnostic solutions accessible to healthcare professionals and, ultimately, the patients in need.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.